{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-040008","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.086764+00:00","generated_at":"2026-06-04T05:58:11.784644+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Milestone Pharmaceuticals resubmits NDA for etripamil nasal spray to FDA for PSVT","bullets":["NDA resubmission for self-administered etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT).","Resubmission follows FDA Type A meeting after a Refusal to File letter; no new efficacy/safety data requested.","Package includes restructured AE timing data and reformatted data files to facilitate FDA review."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-040008","json":"https://secwatch.observer/filing/0001104659-24-040008.json","markdown":"https://secwatch.observer/filing/0001104659-24-040008.md","text":"https://secwatch.observer/filing/0001104659-24-040008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924040008/0001104659-24-040008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924040008/tm2410060d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:58:11.784644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}